Detalhe da pesquisa
1.
Duration of Chemotherapy-Induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles.
Oncologist
; 28(3): 208-213, 2023 03 17.
Artigo
Inglês
| MEDLINE | ID: mdl-36527702
2.
Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602).
Oncologist
; 28(8): 722-729, 2023 08 03.
Artigo
Inglês
| MEDLINE | ID: mdl-37284847
3.
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
Support Care Cancer
; 32(1): 36, 2023 Dec 18.
Artigo
Inglês
| MEDLINE | ID: mdl-38105286
4.
Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis.
Support Care Cancer
; 31(12): 654, 2023 Oct 25.
Artigo
Inglês
| MEDLINE | ID: mdl-37878086
5.
Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin.
Oncologist
; 26(4): 325-331, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33289268
6.
Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis.
Future Oncol
; 17(23): 3027-3035, 2021 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-33878896
7.
Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients.
Support Care Cancer
; 29(8): 4269-4275, 2021 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-33409724
8.
Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.
Support Care Cancer
; 29(7): 3439-3459, 2021 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-33442782
9.
Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy.
Oncologist
; 25(3): e589-e597, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-32162813
10.
What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy.
J Natl Compr Canc Netw
; 18(6): 676-681, 2020 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32502985
11.
Nausea and Vomiting in Advanced Cancer.
Curr Treat Options Oncol
; 21(2): 14, 2020 02 05.
Artigo
Inglês
| MEDLINE | ID: mdl-32025954
12.
Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies.
Future Oncol
; 16(24): 1863-1872, 2020 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-32543309
13.
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
N Engl J Med
; 375(2): 134-42, 2016 Jul 14.
Artigo
Inglês
| MEDLINE | ID: mdl-27410922
14.
HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis.
Future Oncol
; 15(3): 241-255, 2019 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-30304952
15.
Managing Nausea and Vomiting in Patients With Cancer: What Works.
Oncology (Williston Park)
; 32(3): 121-5, 131, 136, 2018 03 15.
Artigo
Inglês
| MEDLINE | ID: mdl-29548068
16.
Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis.
Support Care Cancer
; 26(8): 2519-2549, 2018 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-29796708
17.
Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis.
Support Care Cancer
; 30(2): 1015-1018, 2022 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-34613472
18.
2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
Support Care Cancer
; 25(1): 303-308, 2017 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27815710
19.
Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy.
Support Care Cancer
; 25(1): 85-92, 2017 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27557833
20.
2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy.
Support Care Cancer
; 25(1): 277-288, 2017 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27443154